Alexion Pharmaceuticals Inc.’s Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc., (Nasdaq:ALXN) today announced that the Australian Government’s Therapeutic Goods Administration has approved the use of Soliris® (eculizumab) for the treatment of all patients in Australia with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Australia for the treatment of PNH.